Once‐weekly semaglutide versus insulin aspart for the treatment of type 2 diabetes in the UK: A long‐term cost‐effectiveness analysis based on SUSTAIN 11

AIM: To evaluate the long‐term cost‐effectiveness of once‐weekly semaglutide 1 mg versus insulin aspart in the UK. MATERIALS AND METHODS: Long‐term outcomes were projected over patients' lifetimes using the IQVIA CORE Diabetes Model (vers 9.0). SUSTAIN 11 was used to inform baseline cohort char...

Descripción completa

Detalles Bibliográficos
Autores principales: Evans, Marc, Chubb, Barrie, Malkin, Samuel J. P., Berry, Sasha, Lawson, Jack, Hunt, Barnaby
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092031/
https://www.ncbi.nlm.nih.gov/pubmed/36251282
http://dx.doi.org/10.1111/dom.14892

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092031/
https://www.ncbi.nlm.nih.gov/pubmed/36251282
http://dx.doi.org/10.1111/dom.14892

Ejemplares similares